AI pioneer Innoplexus and phytopharmaceutical company DrD are partnering toRead More
Partnering to unlock the true potential of cannabis in medical care
How Blockchain And AI Can Help Pharma Focus On Innovation Rather Than Advertising
Pharmaceutical companies spend a tremendous amount of money each year on advertising and marketing. According to the Pew Charitable Trusts, “In 2012, the pharmaceutical industry spent more than $27 billion on drug promotion — more than $24 billion on marketing to physicians and over $3 billion on advertising to consumers.“
This strategy is designed to promote drug products by influencing the prescribing practices of doctors. One of the ways out of this advertising spending bubble is to reduce overall ad expenditures and introduce focused advertising with the help of artificial intelligence (AI) and blockchain.
The Enormity Of The Problem
Nine out of the top ten big pharmaceutical firms have been known to consistently spend much more on marketing than on research, which is possibly what has created the underlying problem of unbalanced spending in the industry. For instance, in 2013, Roche was the only big pharma company that spent moremoney on R&D than marketing, with Johnson & Johnson forking over approximately $17.5 billion to sales and marketing, compared to $8.2 billion for its research.
Despite popular outcry for more strict limits on prescription drug ads, the pharmaceutical industry is still pouring billions of dollars into marketing campaigns, especially TV and print. In 2016, advertisement spending increased to a total of $5.2 billion, with more than a 60% increase in spending over the last four years.
Even more interesting, one-quarter of the industry’s $5.2 billion that was spent in 2016 went to advertising just five drugs: Humira (multiple arthritic conditions), Lyrica (nerve and muscle pain), Eliquis (anticoagulant to reduce stroke risk), Cialis (erectile dysfunction) and Xeljanz (rheumatoid arthritis). The data seems to portray a bleak outlook on an otherwise booming industry, showing that only the most profitable drugs gain the most marketing funds instead of a balanced placement of funding for all medications.
Why Does Pharma Advertise?
Why do pharma companies need to advertise at such a large and expensive level? The answer is closely tied to the astronomical expenses associated with drug research, discovery and development. After spending billions of dollars developing a new drug, pharma companies face significant pressure to achieve a positive return on their investment. And the common way to achieve this return is to heavily advertise newly approved products.
Once a company releases a new drug, it has a window of roughly 8 to 10 months during which it has a market monopoly. Because they have the upper hand for such a short time, pharma companies naturally want to burst out of the gate with ads to gain the most revenue they can. Ideally, this advertising will also help secure long-term market share. The problem is not the fact that companies are advertising these drugs but in how they are advertising them. Pharmaceutical companies are still basically advertising like it’s 1975, using “spray and pray” tactics in TV ads and on billboards, which are massively expensive and inefficient in this day and age. By leveraging the technologies of AI and blockchain, the pharmaceutical industry could spend less on advertising by implementing highly focused and segmented campaigns that generate superior results at a fraction of the price.
How Blockchain And AI Can Help
Emerging technologies are making new levels of efficiency possible. A fully transparent and trustworthy blockchain-based system would mean that pharma brands would finally be able to see how much of their spending ends up with the publisher. They would then have the ability to optimize the range of ad tech providers they work with based on value added to the supply chain. As a result, they would avoid overpaying for advertising. They would also be able to steer clear of the $19 billion in fraudulent advertising that occurs worldwide each year, a staggering number calculated by Juniper Research.
Imagine a highly scalable advertising system built on top of blockchain that supports instant transactions between participating pharma companies and prospects. This new approach to advertising could be considered the beginning of a “micro-digital advertising” age in the pharmaceutical industry. AI also has many advertising and marketing applications in segmenting and targeting highly specific audiences.
Other technologies like big data and forms of AI are already employed by contemporary digital advertising platforms that can help companies focus their advertising for greater efficiency and return on investment. Most social media platforms support segmented ad targetting. Plus, the cost of digital ads tends to be much less than the cost of traditional TV advertising, so companies enjoy the double benefit of lower prices and greater cost efficiency.
By utilizing blockchain, AI technology and big data, companies can achieve an unprecedented level segmentation and focused targeting in their advertising. With the spending of pharmaceutical advertising at an all-time high, this is the pharmaceutical industry’s best chance to take advantage of the AI and blockchain
technologies currently under development.
The original article was published on Forbes.
Featured News
Strategic partnership announcement: Innoplexus holding company Partex NV is pleased
Exciting News! Anavex Life Sciences and Partex NV Announce Strategic Partnership to Enhance Patient Experience.Anavex Life Sciences Corp. and Partex NV N.V. Group are pleased to announce…
AI supports targeted therapy recommendations fortumor diseases – BMBF funds
The treatment and support of patients with advanced tumor diseases is a complex task involving numerous disciplines. For the interdisciplinary…
Innoplexus and Innovatrix capital partner to bring about new risk-transfer
Artificial Intelligence (AI) pioneer Innoplexus and London based Parametric Insurance start-up, Innovatrix Capital, collaborating upon using AI & Machine Learning…
Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial
Innoplexus and Inflection Biosciences enter strategic collaboration based on Artificial Intelligence to expedite PIM kinase inhibitor development ESCHBORN, Germany, May 30,…
Parexel and Innoplexus Unveil Single Source of COVID-19 Information for
COVID-19 Clearinghouse enables direct access to latest COVID-19 datasets, publications, research and clinical trialsBOSTON and DURHAM, N.C. and ESCHBORN, Germany,…
New app for cancer patients
Das Eschborner Unternehmen Innoplexus hat eine neue App namens „Curia“ für Krebspatienten veröffentlicht. Mit dem Computerprogramm, das sich unentgeltlich herunterladen…
Innoplexus wins Silver Edison Award for OntosightⓇ Explore
Frankfurt, Germany, March 26, 2020 — Innoplexus AG has been honored with the Silver Edison Award 2020 for its proprietary…
AI CTP engine estimated failure for Biogen’s aducanumab
While drug development can be incredibly lucrative, it is a very risky business. German company Innoplexus has developed a domain-specific…
How can AI be leveraged for Clinical Trial Prediction?
Successful clinical trials occur at a ratio of 1 in 10, costing around $2-$3 billion, with drugs taking 10–12 years…
Innoplexus launches new Blockchain platform for Pharma innovation
If your loved one was diagnosed with a potentially fatal illness, wouldn’t you want all the information possible to be…